The principal behind Biosimilar Review & Report, Stanton Mehr, is a veteran consultant, observer, and writer in the health care industry. Stan has decades of experience publishing on the pharmaceutical, managed care, and health policy areas. Since 2015, he has been reporting and consulting on the biosimilar industry.
At BR&R, we routinely observe, report, and comment on news, clinical trials, and policy issues related to the 351(k) regulatory pathway and process of drug approval, market access, and reimbursement of these agents.
For more information or to reach Stan about the biosimilar industry, please see our Contact page.